As we approach 3rd January 2018 and the coming into force of the MiFID II legislation which changes the landscape for research, we are beginning to see some of the practical implications and complications. Brokers are in the early stages of working out how to structure charging for research, asset managers have already begun cutting their brokers’ lists and a model code of conduct for Research Payment Accounts for institutions has been published.

03 Jul 2017
The Monthly July 2017
Abzena (ABZA:LON), 0 | Allergy Therapeutics plc (AGY:LON), 7.6 | Arbuthnot Banking Group PLC (ARBB:LON), 942 | Avacta Group PLC (AVCT:LON), 31.5 | Burford Capital Limited (BUR:LON), 1,006 | City of London Investment Group PLC (CLIG:LON), 351 | TheraCryf PLC (TCF:LON), 0.3 | Murgitroyd Group (MUR:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.8 | PPHE Hotel Group Limited (PPH:LON), 1,639 | Primary Health Properties PLC (PHP:LON), 97.0 | R.E.A. Holdings plc (RE:LON), 82.2 | Scancell Holdings Plc (SCLP:LON), 9.8 | Sinclair Pharma (SPH:LON), 0 | Oxford BioMedica plc (OXB:LON), 334 | ValiRx PLC (VAL:LON), 0.6

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
The Monthly July 2017
Abzena (ABZA:LON), 0 | Allergy Therapeutics plc (AGY:LON), 7.6 | Arbuthnot Banking Group PLC (ARBB:LON), 942 | Avacta Group PLC (AVCT:LON), 31.5 | Burford Capital Limited (BUR:LON), 1,006 | City of London Investment Group PLC (CLIG:LON), 351 | TheraCryf PLC (TCF:LON), 0.3 | Murgitroyd Group (MUR:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.8 | PPHE Hotel Group Limited (PPH:LON), 1,639 | Primary Health Properties PLC (PHP:LON), 97.0 | R.E.A. Holdings plc (RE:LON), 82.2 | Scancell Holdings Plc (SCLP:LON), 9.8 | Sinclair Pharma (SPH:LON), 0 | Oxford BioMedica plc (OXB:LON), 334 | ValiRx PLC (VAL:LON), 0.6
- Published:
03 Jul 2017 -
Author:
Doug Hawkins -
Pages:
36 -
As we approach 3rd January 2018 and the coming into force of the MiFID II legislation which changes the landscape for research, we are beginning to see some of the practical implications and complications. Brokers are in the early stages of working out how to structure charging for research, asset managers have already begun cutting their brokers’ lists and a model code of conduct for Research Payment Accounts for institutions has been published.